

A Novel Skeletal Dysplasia with Developmental Delay and a Lys650Met Mutation in the Fibroblast Growth Factor 1

American Journal of Human Genetics

64, 722-731

DOI: 10.1086/302275

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cardiac conduction defects associate with mutations in SCN5A. Nature Genetics, 1999, 23, 20-21.	9.4	549
2	FGF3 gain-of-function mutations and short stature syndromes. Trends in Molecular Medicine, 1999, 5, 239.	2.6	0
3	Clinical spectrum of fibroblast growth factor receptor mutations. Human Mutation, 1999, 14, 115-125.	1.1	284
4	Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations. American Journal of Medical Genetics Part A, 1999, 84, 476-480.	2.4	54
5	Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): Phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. American Journal of Medical Genetics Part A, 1999, 85, 53-65.	2.4	106
6	Ocular anterior chamber dysgenesis in craniosynostosis syndromes with a fibroblast growth factor receptor 2 mutation. , 1999, 85, 160-170.		48
7	Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics, 1999, 23, 18-20.	9.4	637
8	Chondrodysplasias. Current Opinion in Orthopaedics, 2000, 11, 347-352.	0.3	3
10	Mutation of the gene encoding the ROR2 tyrosine kinase causes autosomal recessive Robinow syndrome. Nature Genetics, 2000, 25, 423-426.	9.4	242
11	Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene, 2000, 19, 3309-3320.	2.6	237
12	RTK mutations and human syndromes. Trends in Genetics, 2000, 16, 265-271.	2.9	137
13	RTK mutations and human syndromes: when good receptors turn bad. Trends in Genetics, 2000, 16, 368.	2.9	76
14	FGF Receptor Mutations: Dimerization Syndromes, Cell Growth Suppression, and Animal Models. IUBMB Life, 2000, 49, 197-205.	1.5	45
15	The Pleiotropic Effects of Fibroblast Growth Factor Receptors in Mammalian Development.. Cell Structure and Function, 2000, 25, 85-96.	0.5	72
16	Achondroplasia and nail-patella syndrome: the compound phenotype. Journal of Medical Genetics, 2000, 37, 25e-25.	1.5	10
17	Gene Expression and Tibial Dyschondroplasia. Poultry Science, 2000, 79, 1009-1013.	1.5	48
18	FGF Receptor Mutations: Dimerization Syndromes, Cell Growth Suppression, and Animal Models. IUBMB Life, 2000, 49, 197-205.	1.5	27
19	Distinct Missense Mutations of the FGFR3 Lys650 Codon Modulate Receptor Kinase Activation and the Severity of the Skeletal Dysplasia Phenotype. American Journal of Human Genetics, 2000, 67, 1411-1421.	2.6	154

#	ARTICLE	IF	CITATIONS
20	The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans*. <i>Endocrine Reviews</i> , 2000, 21, 23-39.	8.9	262
21	Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors. <i>American Journal of Pathology</i> , 2001, 158, 1955-1959.	1.9	427
22	Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia. <i>Prenatal Diagnosis</i> , 2001, 21, 89-95.	1.1	65
23	Subtle radiographic findings of achondroplasia in patients with Crouzon syndrome with acanthosis nigricans due to an Ala391Glu substitution in FGFR3. <i>American Journal of Medical Genetics Part A</i> , 2001, 98, 75-91.	2.4	47
24	Occurrence of thanatophoric dysplasia type I (R248C) and hypochondroplasia (N540K) mutations in two patients with achondroplasia phenotype. <i>American Journal of Medical Genetics Part A</i> , 2001, 104, 277-281.	2.4	21
25	Premature calvarial synostosis and epidermal hyperplasia (Beare-Stevenson syndrome-like anomalies) resulting from a P250R missense mutation in the gene encoding fibroblast growth factor receptor 3. <i>American Journal of Medical Genetics Part A</i> , 2001, 101, 187-194.	2.4	25
26	No evidence of somatic FGFR3 mutation in various types of carcinoma. <i>Oncogene</i> , 2001, 20, 5059-5061.	2.6	38
27	A Novel Alternatively Spliced Fibroblast Growth Factor Receptor 3 Isoform Lacking the Acid Box Domain Is Expressed during Chondrogenic Differentiation of ATDC5 Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 11031-11040.	1.6	52
28	Identification of Tyrosine Residues in Constitutively Activated Fibroblast Growth Factor Receptor 3 Involved in Mitogenesis, Stat Activation, and Phosphatidylinositol 3-Kinase Activation. <i>Molecular Biology of the Cell</i> , 2001, 12, 931-942.	0.9	121
29	Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. <i>Human Molecular Genetics</i> , 2001, 10, 1255-1264.	1.4	110
30	Interaction of Fibroblast Growth Factor Receptor 3 and the Adapter Protein SH2-B. <i>Journal of Biological Chemistry</i> , 2002, 277, 15962-15970.	1.6	65
31	Skeletal Dysplasias: Craniosynostosis Syndromes and Skeletal Dysplasias Caused by Mutations in Fibroblast Growth Factor Receptor Genes. , 0, , 961-991.		1
32	Genomic Screening of Fibroblast Growth-Factor Receptor 2 Reveals a Wide Spectrum of Mutations in Patients with Syndromic Craniosynostosis. <i>American Journal of Human Genetics</i> , 2002, 70, 472-486.	2.6	238
33	SÃndrome de Crouzon con acantosis nigricans. <i>Anales De PediatrÃa</i> , 2002, 56, 342-346.	0.3	4
34	Some chondrodysplasias with short limbs: Molecular perspectives. <i>American Journal of Medical Genetics Part A</i> , 2002, 112, 304-313.	2.4	63
35	Genes, growth factors and acanthosis nigricans. <i>British Journal of Dermatology</i> , 2002, 147, 1096-1101.	1.4	159
36	Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. <i>European Journal of Human Genetics</i> , 2002, 10, 819-824.	1.4	138
37	Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2002, 3, 381-385.	2.6	36

#	ARTICLE	IF	CITATIONS
38	Insulin-like Growth Factor-1 Rescues the Mutated FGF Receptor 3 (G380R) Expressing ATDC5 Cells From Apoptosis Through Phosphatidylinositol 3-Kinase and MAPK. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 2043-2051.	3.1	34
39	Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. <i>American Journal of Medical Genetics Part A</i> , 2003, 120A, 157-168.	2.4	30
40	Morphogenesis and dysmorphogenesis of the appendicular skeleton. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2003, 69, 102-122.	3.6	84
41	Physiology and pathophysiology of the growth plate. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2003, 69, 123-143.	3.6	120
42	Roles of FGF receptors in mammalian development and congenital diseases. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2003, 69, 286-304.	3.6	107
43	The genetic basis for skeletal diseases. <i>Nature</i> , 2003, 423, 343-348.	13.7	248
44	The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. <i>Oncogene</i> , 2003, 22, 6909-6918.	2.6	79
45	Molecular Basis for the Treatment of Achondroplasia. <i>Hormone Research in Paediatrics</i> , 2003, 60, 60-64.	0.8	13
46	Genetically Altered Mouse Models: the G _α o _{od} , the B _α d, and the U _{gly} . <i>Critical Reviews in Oral Biology and Medicine</i> , 2003, 14, 154-174.	4.4	84
48	A Diagnostic Approach to Skeletal Dysplasias. , 2003, , 375-IX.		7
49	Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. <i>Bone</i> , 2004, 34, 26-36.	1.4	92
50	Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. <i>Human Molecular Genetics</i> , 2005, 14, 1153-1160.	1.4	175
51	FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis. <i>Clinical Cancer Research</i> , 2005, 11, 5444-5450.	3.2	122
52	High specificity of head circumference to recognize N540K mutation in hypochondroplasia. <i>Annals of Human Biology</i> , 2005, 32, 782-788.	0.4	7
53	Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. <i>Experimental Cell Research</i> , 2005, 304, 417-431.	1.2	196
54	FGFR3 regulates brain size by controlling progenitor cell proliferation and apoptosis during embryonic development. <i>Developmental Biology</i> , 2005, 279, 73-85.	0.9	83
55	Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. <i>Molecular Cancer</i> , 2005, 4, 15.	7.9	61
56	A Novel Mutation in FGFR3 Causes Camptodactyly, Tall Stature, and Hearing Loss (CATSHL) Syndrome. <i>American Journal of Human Genetics</i> , 2006, 79, 935-941.	2.6	129

#	ARTICLE	IF	CITATIONS
57	K644E/M FGFR3 Mutants Activate Erk1/2 from the Endoplasmic Reticulum through FRS2 β and PLC β 3-independent Pathways. <i>Journal of Molecular Biology</i> , 2006, 357, 783-792.	2.0	34
58	A Term Newborn With Congenital Dwarfism. <i>NeoReviews</i> , 2006, 7, e280-e284.	0.4	0
59	A case of Beare's Stevenson syndrome with a broad spectrum of features and a review of the FGFR2 Y375C mutation phenotype. <i>Clinical Dysmorphology</i> , 2006, 15, 89-93.	0.1	23
60	Modulation of β -catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3. <i>Oncogene</i> , 2006, 25, 7166-7179.	2.6	33
61	Sprouty Genes Are Expressed in Osteoblasts and Inhibit Fibroblast Growth Factor-Mediated Osteoblast Responses. <i>Calcified Tissue International</i> , 2006, 78, 233-240.	1.5	23
62	The new bone biology: Pathologic, molecular, and clinical correlates. <i>American Journal of Medical Genetics, Part A</i> , 2006, 140A, 2646-2706.	0.7	257
63	MUC1 Oncoprotein Functions in Activation of Fibroblast Growth Factor Receptor Signaling. <i>Molecular Cancer Research</i> , 2006, 4, 873-883.	1.5	80
64	Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLC β 3-activated STAT1. <i>Bone</i> , 2007, 41, 273-281.	1.4	29
65	PTH has the potential to rescue disturbed bone growth in achondroplasia. <i>Bone</i> , 2007, 41, 13-18.	1.4	39
66	Human immortalized chondrocytes carrying heterozygous FGFR3 mutations: An in vitro model to study chondrodysplasias. <i>FEBS Letters</i> , 2007, 581, 2593-2598.	1.3	10
67	Achondroplasia. <i>Lancet, The</i> , 2007, 370, 162-172.	6.3	456
68	Third-trimester 3D Ultrasound Evaluation of Thanatophoric Dysplasia Type I. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2007, 46, 281-283.	0.5	6
69	Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene. <i>American Journal of Medical Genetics, Part A</i> , 2007, 143A, 3144-3149.	0.7	25
70	Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. <i>Differentiation</i> , 2007, 75, 831-842.	1.0	69
71	Fibroblast growth factor receptor 3 kinase domain mutation increases cortical progenitor proliferation via mitogen-activated protein kinase activation. <i>Journal of Neurochemistry</i> , 2007, 100, 070209222715073-???	2.1	30
72	The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor. <i>FEBS Journal</i> , 2007, 274, 3078-3093.	2.2	37
73	FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 502-512.	1.9	30
74	Prenatal and postnatal presentation of severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) due to the FGFR3 Lys650Met mutation. <i>American Journal of Medical Genetics, Part A</i> , 2008, 146A, 212-218.	0.7	21

#	ARTICLE	IF	CITATIONS
75	Achondroplasia. Best Practice and Research in Clinical Rheumatology, 2008, 22, 3-18.	1.4	117
76	Genetics of Craniosynostosis: Genes, Syndromes, Mutations and Genotype-Phenotype Correlations. Frontiers of Oral Biology, 2008, 12, 107-143.	1.5	134
77	Nordihydroguaiaretic Acid Inhibits an Activated Fibroblast Growth Factor Receptor 3 Mutant and Blocks Downstream Signaling in Multiple Myeloma Cells. Cancer Research, 2008, 68, 7362-7370.	0.4	35
78	Hypochondroplasia and acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene?. European Journal of Endocrinology, 2008, 159, 243-249.	1.9	30
79	FGF signaling: its role in bone development and human skeleton diseases. Frontiers in Bioscience - Landmark, 2008, 13, 2842.	3.0	50
80	Malignant Acanthosis Nigricans with Enhanced Expression of Fibroblast Growth Factor Receptor 3. Acta Dermato-Venereologica, 2009, 89, 435-437.	0.6	14
81	FGFR3-related dwarfism and cell signaling. Journal of Bone and Mineral Metabolism, 2009, 27, 9-15.	1.3	43
82	Increased p21 expression in chondrocytes of achondroplastic children independently from the presence of the G380R FGFR3 mutation. Journal of Orthopaedic Science, 2009, 14, 623-630.	0.5	10
83	Prenatal diagnosis of skeletal dysplasia due to FGFR3 gene mutations: a 9-year experience. Journal of Assisted Reproduction and Genetics, 2009, 26, 455-460.	1.2	18
84	The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery, 2009, 8, 235-253.	21.5	1,548
85	Signaling from Fibroblast Growth Factor Receptors in Development and Disease. , 2010, , 1939-1947.		0
86	Targeting mutant fibroblast growth factor receptors in cancer. Trends in Molecular Medicine, 2011, 17, 283-292.	3.5	112
87	FGF and ROR2 Receptor Tyrosine Kinase Signaling in Human Skeletal Development. Current Topics in Developmental Biology, 2011, 97, 179-206.	1.0	11
88	Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opinion on Therapeutic Targets, 2011, 15, 829-846.	1.5	48
89	Hypochondroplasia in a Child With 1620c>G (Asn540Iys) Mutation in FGFR3. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2012, 4, 220-2.	0.4	6
90	p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice. Journal of Clinical Investigation, 2012, 122, 2153-2164.	3.9	47
91	A Diagnostic Approach to Skeletal Dysplasias. , 2012, , 403-437.		6
92	Sixteen years and counting: The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Human Mutation, 2012, 33, 29-41.	1.1	163

#	ARTICLE	IF	CITATIONS
93	Cracking the Molecular Origin of Intrinsic Tyrosine Kinase Activity through Analysis of Pathogenic Gain-of-Function Mutations. <i>Cell Reports</i> , 2013, 4, 376-384.	2.9	44
94	Chondrodysplasias. , 2013, , 1-45.		2
95	Cutaneous Features of Crouzon Syndrome With Acanthosis Nigricans. <i>JAMA Dermatology</i> , 2013, 149, 737.	2.0	24
96	Acanthosis Nigricans Associated with an Adrenocortical Tumor in a Pediatric Patient. <i>Case Reports in Endocrinology</i> , 2013, 2013, 1-4.	0.2	1
97	The best-laid plans go oft awry: synaptogenic growth factor signaling in neuropsychiatric disease. <i>Frontiers in Synaptic Neuroscience</i> , 2014, 6, 4.	1.3	36
98	Novel Lys63-linked ubiquitination of IKK $\hat{\kappa}$ ² induces STAT3 signaling. <i>Cell Cycle</i> , 2014, 13, 3964-3976.	1.3	20
99	The paradox of FGFR3 signaling in skeletal dysplasia: Why chondrocytes growth arrest while other cells over proliferate. <i>Mutation Research - Reviews in Mutation Research</i> , 2014, 759, 40-48.	2.4	41
100	Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 243-250.	0.7	3
101	Statins give bone growth a boost. <i>Nature</i> , 2014, 513, 494-495.	13.7	1
102	How calcium affects oxygen formation. <i>Nature</i> , 2014, 513, 495-496.	13.7	18
103	ã,1ã,;ãfãf3ã~é"ã@æ^é•ã,'ã;fã™. <i>Nature Digest</i> , 2014, 11, 24-25.	0.0	0
104	Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models. <i>Bone Research</i> , 2014, 2, 14003.	5.4	196
105	Signaling Pathways in Craniofacial Development. <i>Current Topics in Developmental Biology</i> , 2015, 115, 493-542.	1.0	20
106	A novel mutation Ser344Cys in <i>FGFR3</i> causes achondroplasia with severe platyspondyly. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 2851-2854.	0.7	13
107	Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 425-449.	3.2	125
108	FGFR3-related condition: a skeletal dysplasia with similarities to thanatophoric dysplasia and SADDAN due to Lys650Met. <i>Skeletal Radiology</i> , 2015, 44, 441-445.	1.2	5
109	Fibroblast growth factor signaling in skeletal development and disease. <i>Genes and Development</i> , 2015, 29, 1463-1486.	2.7	299
110	Meclozine Promotes Longitudinal Skeletal Growth in Transgenic Mice with Achondroplasia Carrying a Gain-of-Function Mutation in the FGFR3 Gene. <i>Endocrinology</i> , 2015, 156, 548-554.	1.4	44

#	ARTICLE	IF	CITATIONS
111	Molecular Defects and Cellular Dysfunctions in Restricted Growth Conditions. , 2016, , .		0
112	Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis. Hormone Research in Paediatrics, 2016, 86, 27-34.	0.8	38
113	Protein-losing enteropathy with intestinal lymphangiectasia in skeletal dysplasia with Lys650Met mutation. American Journal of Medical Genetics, Part A, 2016, 170, 2993-2997.	0.7	2
114	Altered FGF signalling in congenital craniofacial and skeletal disorders. Seminars in Cell and Developmental Biology, 2016, 53, 115-125.	2.3	35
115	Perinatal imaging findings and molecular genetic analysis of thanatophoric dysplasia type 1 in a fetus with a c.2419T>G (p.Ter807Gly) (X807G) mutation in FGFR3. Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 87-92.	0.5	3
116	Achondroplasia: Development, pathogenesis, and therapy. Developmental Dynamics, 2017, 246, 291-309.	0.8	160
117	Imaging of Skeletal Disorders Caused by Fibroblast Growth Factor Receptor Gene Mutations. Radiographics, 2017, 37, 1813-1830.	1.4	28
118	FGF23-Î±Klotho as a paradigm for a kidney-bone network. Bone, 2017, 100, 4-18.	1.4	76
119	Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCÎ³1/Src-mediated paxillin hyperphosphorylation. International Journal of Biochemistry and Cell Biology, 2018, 95, 17-26.	1.2	8
120	Familial acanthosis nigricans with p.K650T <i><sc>FGFR</sc>3</i> mutation. Journal of Dermatology, 2018, 45, 207-210.	0.6	17
121	Familial acanthosis nigricans with the <i><sc>FGFR</sc>3</i> mutation: Differences of pigmentation between male and female patients. Journal of Dermatology, 2018, 45, 1357-1361.	0.6	6
122	Nanodiamonds as "artificial proteins": Regulation of a cell signalling system using low nanomolar solutions of inorganic nanocrystals. Biomaterials, 2018, 176, 106-121.	5.7	27
123	Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants. American Journal of Medical Genetics, Part A, 2018, 176, 1675-1679.	0.7	7
124	Achondroplasia and Other FGFR3-related Short Limbed Dysplasia: Molecular Heterogeneity and Therapeutic Approaches. Colloquium Series on Genomic and Molecular Medicine, 2018, 7, i-52.	0.2	0
125	Mild osteochondrodysplasia with acanthosis nigricans in a short-statured Taiwanese family due to the p.Lys650Gln mutation in FGFR3. Pediatrics and Neonatology, 2019, 60, 686-688.	0.3	1
126	Fibroblast growth factors in skeletal development. Current Topics in Developmental Biology, 2019, 133, 195-234.	1.0	46
127	Achondroplasia: a comprehensive clinical review. Orphanet Journal of Rare Diseases, 2019, 14, 1.	1.2	292
128	Fibroblast growth factor (FGF) and FGF receptor families in bone. , 2020, , 1113-1140.		0

#	ARTICLE	IF	CITATIONS
129	Fibroblast growth factor receptor signaling as therapeutic targets in female reproductive system cancers. <i>Journal of Cancer</i> , 2020, 11, 7264-7275.	1.2	12
130	Enhanced FGFR3 activity in postmitotic principal neurons during brain development results in cortical dysplasia and axonal tract abnormality. <i>Scientific Reports</i> , 2020, 10, 18508.	1.6	7
131	Autosomal dominant familial acanthosis nigricans caused by a C-terminal nonsense mutation of FGFR3. <i>Journal of Human Genetics</i> , 2021, 66, 831-834.	1.1	3
132	Growth Topics in FGFR3-Related Skeletal Dysplasias. <i>Current Treatment Options in Pediatrics</i> , 2021, 7, 82-98.	0.2	2
133	Signaling Pathways in Bone Development and Their Related Skeletal Dysplasia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4321.	1.8	25
134	Cilia kinases in skeletal development and homeostasis. <i>Developmental Dynamics</i> , 2022, 251, 577-608.	0.8	3
136	Fibroblast Growth Factor Receptor and Related Skeletal Disorders. , 2016, , 177-187.		1
138	Activating Somatic FGFR2 Mutations in Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e60264.	1.1	29
139	Meclozine Facilitates Proliferation and Differentiation of Chondrocytes by Attenuating Abnormally Activated FGFR3 Signaling in Achondroplasia. <i>PLoS ONE</i> , 2013, 8, e81569.	1.1	46
140	Pediatric Bone Disease. , 2002, , 217-240.		1
144	Growth in Thanatophoric Dysplasia. , 2012, , 2349-2363.		0
145	Degenerative and metabolic diseases. , 2012, , 520-589.		6
148	Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood. <i>Annals of Pediatric Endocrinology and Metabolism</i> , 2022, 27, 90-97.	0.8	5